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Abstract: Primary care integration of Down syndrome (DS)-specific dementia screening is strongly
advised. The current study employed principal components analysis (PCA) and classification and
regression tree (CART) analyses to identify an abbreviated battery for dementia classification. Scaleand subscale-level scores from 141 participants (no dementia n = 68; probable Alzheimer’s disease
n = 73), for the Severe Impairment Battery (SIB), Dementia Scale for People with Learning Disabilities (DLD), and Vineland Adaptive Behavior Scales—Second Edition (Vineland-II) were analyzed.
Two principle components (PC1, PC2) were identified with the odds of a probable dementia diagnosis increasing 2.54 times per PC1 unit increase and by 3.73 times per PC2 unit increase. CART
analysis identified that the DLD sum of cognitive scores (SCS < 35 raw) and Vineland-II community
subdomain (<36 raw) scores best classified dementia. No significant difference in the PCA versus
CART area under the curve (AUC) was noted (D(65.196) = −0.57683; p = 0.57; PCA AUC = 0.87; CART
AUC = 0.91). The PCA sensitivity was 80% and specificity was 70%; CART was 100% and specificity
was 81%. These results support an abbreviated dementia screening battery to identify at-risk individuals with DS in primary care settings to guide specialized diagnostic referral.
Keywords: Down syndrome; dementia; cognition; functional independence; neuropsychological assessment; primary care; screening
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1. Introduction
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Down syndrome (DS), a genetic condition caused predominantly by the triplication
of chromosome 21, is highly associated with the development of Alzheimer’s disease (AD)
[1]. Chromosome 21 includes the amyloid precursor protein (APP) gene, and triplication
results in overexpression of APP and related proteins, accelerating the accumulation of
misfolded amyloid in the brain [2–4]. Additional AD risk factors are also associated with
DS including a higher propensity for neuroinflammation, oxidative damage, sleep apnea,
and reduced cognitive reserve due to premorbid intellectual disability [1,5–7]. Indeed, AD
pathological changes have been documented in adults with DS as young as 20 years, and
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nearly all adults with DS show the amyloid plaques and neurofibrillary tangles associated
with AD by 40 years of age [8–10].
DS is associated with different physical morphology, intellectual disabilities, and reduced lifespan compared to the typically developing population. Associated health problems include atlantoaxial instability, musculoskeletal and dental conditions, congenital
heart disease, hematologic conditions, obesity, hypothyroidism, obstructive sleep apnea,
impaired hearing and vision, and overall increased functional dependence due to behavioral, psychiatric, and intellectual impairments [7,11–14]. Advances in medical management of these co-morbidities have lowered mortality from early-life conditions, but one
consequence of lengthened lifespan is that more individuals with DS now survive to the
age of risk for AD [15].
Due to the need for preventative care and ongoing management of chronic health
conditions associated with DS, health professionals and advocacy groups recommend the
integration of DS-specific care in primary care settings [14,16,17]. Healthcare systems have
made progress toward this end, but there is a need for improvement [11,18]. Cognitive
screening and monitoring for dementia is particularly difficult, as cognitive measurement
is complicated by pre-existing intellectual disability (ID), large inter- and intra-individual
variability in cognition and behavior, tolerability of testing methods, and the lack of an
identified “gold standard” neurocognitive battery, even for research purposes [19,20].
Moreover, neurocognitive tests are not feasible in primary care settings due to the lengthy
procedures and specialized training needed for the interpretation of comprehensive evaluations.
In recent studies, our group has sought to establish an evidence base for abbreviated
neurobehavioral examination procedures appropriate for in-office dementia monitoring
by community practitioners caring for patients with DS [21]. Performance measures in our
long-term cohort studies include the Brief Praxis Test (BPT) [22] and the Severe Impairment Battery (SIB) [23]. Informant measures included the Dementia Questionnaire for
People with Learning Disabilities (DLD) [24] and Vineland Adaptive Behavior Scales-Second Edition (Vineland-II) [25]. The BPT, SIB, and DLD have all been used in early DS
clinical trials assessing the effects of anticholinesterase therapy [26] as well as antioxidants
[27,28]. Moreover, the SIB has long been validated as a cognitive measure for severe impaired individuals with AD [29]. The Vineland-II has been widely used and validated in
the DS population [30–32] and adaptive behavior decline is a diagnostic criterion for AD,
necessitating the inclusion of this type of measure in this study. These measures were
selected at the outset of the two parent cohorts from which the present data are drawn,
and target the domains of cognition (SIB, DLD), praxis (BPT), and functional independence (DLD, Vineland-II) that underlie both NINCDS-ADRDA and DSM-IV criteria for dementia/major neurocognitive disorder.
The present study seeks to further identify the key components that are useful for
dementia detection through three aims:
•
•
•

Aim 1: to identify the underlying components of a cognitive battery that was used to
assess functioning in domains commonly affected by AD.
Aim 2: to select the minimum necessary individual items or subscales using CART
analysis to create an abbreviated battery for classifying AD status.
Aim 3: to compare the classification accuracy between the two methods: components
from the full battery vs. the abbreviated battery.

2. Materials and Methods
2.1. Description of Sample
The current study combines participants from cohorts at two different sites: the University of Kentucky and the University of California, Irvine (UCI). The University of Kentucky Aging and Down Syndrome (ADS) study is a longitudinal cohort of aging individuals with DS. For the purpose of the current study, only the baseline visit was used for 88
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participants. Twenty-nine of the original one hundred and seventeen participants in the
overall ADS study were unable to contribute data for the present analysis, predominantly
due to inability to engage in testing because of advanced dementia. The University of
Kentucky ADS cohort recruited individuals with DS between 25 and 64 years of age. From
the UCI cohort, only the baseline visit was used for 53 participants. One of the original 54
participants in the overall UCI study was unable to contribute data for the present analysis
due to inability to engage in testing because of advanced dementia. The UCI cohort included people between 43 and 58 years of age.
A karyotype diagnosis of trisomy 21 (full or mosaic) or the Robertsonian translocation form of DS was required. Baseline levels of ID were determined by caregiver report
of prior evaluation results or by a review of records when available. Other requirements
for study inclusion included a stable medical condition for at least 3 months prior to the
study and to have an absence of systemic disorders that might confound a diagnosis of
dementia. Medication usage including psychotropic and Parkinsonian drugs was required to be stable for 3 months prior to study, and English-speaking skills were required
to facilitate neuropsychological testing.
Research procedures were independently reviewed and approved by the University
of Kentucky Institutional Review Board and the UCI Institutional Review Board. Participants completed approved protocols for informed consent or assent with guardian or legally authorized representative approval.
2.2. Description of Measures
Both sites administered a combination of performance and informant measures that
have been used with adults with DS. Performance measures included the BPT and SIB,
and informant measures included the DLD and Vineland-II.
The BPT is a 20-item measure of dyspraxia that minimizes verbal demands in favor
of simple behavioral output. Low scores on the BPT indicate severe dyspraxia.
The SIB utilizes one-step commands and gestural cues, and allows for non-verbal
responses and partially correct responses in order to assess cognition in individuals with
severe dementia. The SIB yields a total score along with six major subscales for attention,
orientation, language, memory, visuospatial ability, and construction, with additional
scores for orientation to name, praxis, and social interaction. Lower scores indicate more
severe deficits.
The DLD is a 50-item informant questionnaire measuring behavioral and cognitive
dysfunction. The DLD yields three scores: (1) sum of cognitive score (SCS), measuring
short-term memory, long-term memory, and spatial/temporal orientation; (2) sum of social score (SOS), measuring speech, practical skills, mood, activity/interest, and behavioral
disturbance; and (3) a total score that combines the SCS and SOS. DLD raters for the current study were caregivers and/or legal guardians responsible for the daily care of the
participants either at home or an assisted living facility. Higher scores on the DLD indicate
more severe impairment.
The Vineland-II is an informant-based measure covering domains of communication,
daily living skills, socialization, motor skills, and maladaptive behavior. The Vineland-II
provides a composite score reflecting an individual’s overall adaptive behavior functioning, called the Adaptive Behavior Composite (ABC). The Vineland-II is administered by a
trained interviewer to the parent or caregiver.
2.2.1. Consensus Diagnosis
AD diagnosis, based on NINCDS-ADRDA or DSM-IV criteria [33,34], was made at
each site using a consensus process involving a neurologist and a psychologist. The SIB,
BPT, and DLD test data were used in consensus diagnosis decisions. The diagnosis of dementia required a clinical and neurological examination showing deficits in 2 or more
areas of cognitive functioning, and progressive worsening of cognitive performance compared to the potential participant’s baseline functioning.
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2.2.2. Data Preparation
Raw scores were used for all measures except for the Vineland-II domain-level scores
(ABC, communication, daily living skills, socialization, and motor skills), which were only
available as standardized scores. No subscales were removed for excessive missingness
(>15% of data points missing across individuals). The DLD had the least amount of missing data (0.71% missing), followed by the Vineland-II (9.22% missing) and the SIB (9.93%
missing). Missing data were imputed using chained random forests via the ‘missRanger’
R package [35]. Next, the DLD scores were inverted for consistent directionality with the
other measures. All analyses were completed in R v 4.0.0 [36] and the significance level
set to 0.05.
Aim 1: Principal Components Analysis
For the first aim, principal components analysis (PCA) was used to identify the number of components assessed by all individual items from the performance and informant
procedures. The R package ‘tidymodels’ was used for all steps of the PCA analysis. The
appropriateness of using PCA was evaluated using variable correlations, Bartlett’s test,
Kaiser-Meyer-Olkin, and determinants. In terms of correlations, variables should be only
mildly intercorrelated and were examined using thresholds suggested by Field et al. [37]
to have absolute correlations ranging from 0.3 to 0.9. Items with more than one occurrence
for a correlation outside of the range were excluded from the PCA analysis. Only four
variables needed to be excluded: Vineland-II ABC, Vineland-II social domain score, one
item from the Vineland-II maladaptive behavior domain scale, and the SIB total score. The
Kaiser-Meyer-Olkin factor adequacy was 0.95, above the 0.7 threshold. Bartlett’s test of
sphericity was significant (X2(325) = 5207.62; p < 0.001). Finally, the determinant was below
0.00001. Together, these indicated that PCA was appropriate. Based on the scree plot of
unrotated results, two components with eigenvalues > 1.0 were identified, accounting for
76% of the total variance in scores. Varimax rotation of loadings was then employed to
enhance interpretability of identified components.
The dataset containing the two components scores and AD diagnostic status were
then split into a training and test dataset. The training dataset was used to generate the
logistic regression model. The model was assessed for multicollinearity and the assumption that independent variables are linearly related to the log odds. The performance of
the generated model was assessed on the test dataset by evaluating the area under the
curve (AUC), sensitivity, and specificity.
Aim 2: Classification and Regression Tree Analysis
For the second aim, classification and regression tree (CART) modeling was used to
identify an optimal set of rules for classifying participants by diagnosis based only on
item- and subscale-level data from the neurobehavioral battery. Again, R package ‘tidymodels’ was used in all steps of the CART analysis. First, training and test datasets were
generated from the data. Then, the training dataset was used to generate a set of 10-fold
cross-validation samples for model hyperparameter tuning. The best hyperparameters
were selected based on the AUC. The CART model was first fit on the training dataset,
then on the test dataset to assess performance.
Aim 3: Receiver Operating Characteristic Curves and Comparisons
For the third aim, to compare the relative utility of the PCA and CART models, the
AUC of both models for classifying diagnosis were compared using the bootstrap test for
comparing ROC curves (R routine ‘roc.test’ from the package ‘pROC’). Sensitivity, specificity, and positive and negative predictive values were computed for the PCA and CART
models.
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3. Results
3.1. Sample Characteristics
A total of 141 participants were included in the current study. Just over half of the
participants (n = 73; 51.77%) were diagnosed with probable AD. Full participant characteristics are provided in Table 1.
Table 1. Participant Characteristics.

Characteristic
No Dementia, N = 68
Sex
Female
36 (52.94%)
Male
32 (47.06%)
Age (years)
38.11 (9.34)
Level of Intellectual
Disability (estimated)
Mild
3 (4.41%)
Moderate
36 (52.94%)
Profound
28 (41.18%)
Severe
1 (1.47%)
Unknown
0 (0.00%)
Site
UCI
0 (0.00%)
UKY
68 (100.00%)

Probable AD, N = 73

Overall, N = 141

41 (56.16%)
32 (43.84%)
52.68 (6.12)

77 (54.61%)
64 (45.39%)
45.66 (10.70)

14 (19.18%)
29 (39.73%)
15 (20.55%)
13 (17.81%)
2 (2.74%)

17 (12.06%)
65 (46.10%)
43 (30.50%)
14 (9.93%)
2 (1.42%)

53 (72.60%)
20 (27.40%)

53 (37.59%)
88 (62.41%)

n (%); mean (SD).

3.2. Aim 1: Principal Components Analysis Results
Results of the PCA are listed in supplementary Table S1. The two components could
not be easily labeled because they each contained items from communication, daily living
skills, and cognitive domains. For the PCA method, logistic regression results demonstrated that higher scores on PC1 and PC2 were predictive of AD diagnosis. For each unit
increase in PC1, the odds of a probable dementia diagnosis increased 2.54 times, and for
each unit increase in PC2 the odds of a probable dementia diagnosis increased 3.73 times
(Table 2).
Table 2. Logistic Regression.

Predictors
(Intercept)
PC1
PC2
Observations
Tjur’s R2

Odds Ratio
1.14
2.54
3.73
106
0.786

95% CI
0.46–2.84
1.69–3.81
1.62–8.60

p
0.773
<0.001
0.002

n (%); mean (SD).

3.3. Aim 2: Classification and Regression Tree Analysis Results
The CART analysis revealed that the DLD SCS and Vineland-II community subdomain raw scores best-classified dementia (Figure 1). A DLD SCS less than 35 and a Vineland community score less than 34 are indicative of AD dementia.
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Figure 1. Results of CART analysis. Note. AD = Alzheimer’s disease; DLD SCS = Dementia Questionnaire for People with
Learning Disabilities (DLD) sum of cognitive scores raw score; CMM Raw = Vineland-II community subdomain raw score.

3.4. Aim 3: Comparison of PCA and CART Model Classification Utility
Comparing the PCA logistic regression and CART classification methods, there was
no significant difference in AUC (D(65.196) = −0.57683; p = 0.57) (Figure 2). The PCA analysis resulted in an AUC of 0.87 while the CART model produced an AUC of 0.91. In terms
of classification utility, the PCA model showed very good sensitivity (0.80) and good specificity (0.70), with high negative predictive value (0.824) and moderately high positive
predictive value (0.667) at the combined sample base rate. The CART model demonstrated
excellent sensitivity (1.00) and very good specificity (0.810), with excellent negative predictive value (1.00) and high positive predictive value (0.778) at the combined sample base
rate.

Figure 2. ROC curve comparison for PCA versus CART derived models. PCA area under the curve
(AUC) = 0.87, and CART model AUC = 0.91.
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4. Discussion
The present data indicate that for adults with DS, variability in orientation, language,
memory, visuospatial skills, praxis, mood, and social participation is largely explained by
two underlying principal components. These two components seemed to differentiate
cognitive from practical function (i.e., the ability to answer questions vs. the ability to
carry out everyday tasks). Additionally, the use of the two-component model to categorize participants with respect to AD dementia status showed high classification accuracy.
These findings support the further distillation of the modest-sized battery into a “short
form” that can be easily administered in a primary care setting. Additionally, it takes less
than an hour to administer to an informant who knows the patient with DS well, and
requires minimal office space and test stimuli.
Results of the CART analysis also demonstrated that a small subset of the original
battery—the cognitive subscale of the DLD (SCS) and the community subscale of the Vineland-II—were just as effective in classifying AD dementia status. However, the CART
model exhibited better negative predictive value, in that fewer participants with dementia
were misclassified as non-demented compared to the principal components model. A
short battery based on the CART model is also quicker to administer and can in most cases
be completed in less than 30 min.
A key finding is that the two contributory measures are not direct, objective measures
of cognitive performance completed by the patient. Instead, they are informant-based
scores of the patient’s observed changes in cognitive abilities (DLD-SCS) and self-management in community tasks (Vineland-II community). Unexpectedly, classification did
not appreciably hinge on objective, performance-based neurocognitive measures. This
highlights the critical component of informed caregiver ratings when screening for dementia in DS populations and provides some assurance that differential diagnosis of AD
dementia is still possible when a patient’s cognitive abilities cannot be directly assessed
due to profound ID, limited cooperation, sensory impairments, or speech and language
disorders.
Overall, the present data suggest that in clinical contexts with limited time and access
to advanced training in test administration, the cognitive subscale of the DLD and community subscale of the Vineland-II, two widely available instruments, may suffice for
screening and monitoring purposes. To be clear, we do not conclude that these two subscales constitute a comprehensive research or diagnostic battery, as definitive diagnosis
should be based on longitudinal data. Nor is it the case that objective neurocognitive performance measures are redundant for diagnostic purposes. On the contrary, diagnostic
criteria require objective neurocognitive assessment in order to make a firm diagnosis [33].
The present analysis was conducted for the specific aims of the study, namely identifying
measures for resource-limited healthcare settings to encourage wide adoption of dementia screening among community DS practitioners. Prior efforts to use data reduction approaches to streamline a cognitive and behavioral battery for dementia in DS were focused
primarily on developing a minimal comprehensive battery for research and specialty evaluation settings; thus, the resulting recommendations were not as relevant to primary care
screening [38].
Furthermore, the present findings do not suggest that these two subscales represent
an advancement in the early detection of AD dementia relative to more comprehensive
test batteries. Instead, the benefit of adopting a minimal screening battery would enable
more of the broader DS population to be evaluated, who may otherwise go unassessed.
At the individual level, “early” detection is relative to the person’s typical access to care,
not the recommended standard of care. Given that nearly half of adults with DS do not
receive regular screening for typical DS-associated health problems [11], it is reasonable
to cast a wider net with “good enough” measures easily administered in primary care
settings. Moreover, operating characteristics of the CART model align with a preference
for high sensitivity (potential over-identification) over high specificity because the goal of
screening is to provide support to this population.
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Examination of the factor structure and of the item- and subscale-level operating
characteristics in diagnostic batteries for dementia in DS is relatively new ground, and it
is difficult to contextualize the present findings in the literature on the constructs measured. Broadly speaking, these data are in line with indications that adults with DS have
reduced—but not absent—functional independence relative to other adults with intellectual disabilities [39], and dementia-related impairment in that domain may be captured
by a community functioning measure such as the Vineland-II community subscale. Prior
work using the Vineland-II to predict AD dementia in DS found that informant-rated receptive language skills, in addition to performance on a semantic verbal fluency task, were
strong indicators of mild cognitive impairment in DS [40]. The present analysis instead
examined individuals with and without AD dementia and found community management skills to be the most informative subscale of the Vineland-II. These findings are not
contradictory, as in the present study it is likely that variability between participants cognitive functioning were captured by the DLD-SCS informant-based score, leaving more
contextual community-based functioning to be best represented by the Vineland-II community subscale.
Beyond those discussed above, additional limitations of this study include the use of
the SIB, DLD, and BPT along with the neurologic examination to determine consensus
diagnosis. Our prior investigations have found that in 96% of cases, the final consensus
diagnosis matched the neurologist’s diagnosis that was formed independently of the SIB,
BPT, and DLD scores. Still, discussion with the informant allows exposure to much of the
same information captured by these instruments, and consideration of this information
when forming a diagnosis is unavoidable. The eventual goal of both study cohorts is to
substantiate consensus diagnoses with neuropathology at autopsy, allowing a more direct
evaluation of the influence of potential criterion contamination. Additionally, the present
study relied on informants who were very familiar with the participants with DS being
rated, and in many cases, such a source of information cannot be found in practice.
Supplementary Materials: The following are available online at www.mdpi.com/article/10.3390/brainsci11091128/s1, Table S1: Principal Components Analysis Results.
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